Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. (2020)

First Author: Rushworth LK
Attributed to:  Warwick Integrative Synthetic Biology Centre funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41416-019-0681-5

PubMed Identifier: 31844184

Publication URI: http://europepmc.org/abstract/MED/31844184

Type: Journal Article/Review

Volume: 122

Parent Publication: British journal of cancer

Issue: 4

ISSN: 0007-0920